Showing 5031-5040 of 6036 results for "".
- Fewer New Cases of Intraocular Inflammation After First Year of Abicipar in AMD Patientshttps://modernod.com/news/fewer-new-cases-of-intraocular-inflammation-after-first-year-of-abicipar-in-amd-patients/2478703/Most cases of intraocular inflammation in patients with neovascular age-related macular degeneration (nAMD) who take AbbVie’s investigational drug abicipar pegol develop during the first year of treatment, according to a new report of two-year efficacy and safety results from a couple of pi
- Eyenovia Submits New Drug Application to FDA for Pharmacologic Mydriasis with MydCombihttps://modernod.com/news/eyenovia-submits-nda-to-fda-for-pharmacologic-mydriasis-with-mydcombi/2478701/Eyenovia announced that it has submitted a new drug application (NDA) to the FDA for MydCombi, a fixed combination mydriatic (pupil dilation) agent. If approved, MydCombi would be the first microdosed ocular therapeutic with a high precision smart delivery system. The NDA submission follow
- Timing of Cataract Removal in Infancy May Affect Glaucoma Riskhttps://modernod.com/news/timing-of-cataract-removal-in-infancy-may-affect-glaucoma-risk/2478700/A decade after undergoing cataract removal in infancy a substantial and increasing proportion of patients develop glaucoma or become glaucoma suspects, according to a secondary analysis of a randomized clinical trial, Reuters reported.
- Conbercept Treatment of Wet AMD Completes 36-Week Primary Endpoint Visits of Phase 3 Trialhttps://modernod.com/news/conbercept-treatment-of-wet-amd-completes-36-week-primary-endpoint-visits-of-phase-3-trial/2478698/China-based Chengdu Kanghong Pharmaceutical Group announced a key development milestone of its key product conbercept last month. Kanghong is seeking global approval of conbercept by undertaking a multicenter, multinational, d
- Iridex Announces MicroPulse Transscleral Laser Therapy Now Accepted in the European Glaucoma Society Guidelineshttps://modernod.com/news/iridex-announces-micropulse-transscleral-laser-therapy-now-accepted-in-the-european-glaucoma-society-guidelines/2478696/Iridex reported that MicroPulse Transscleral Laser Therapy (TLT), which is performed using the Iridex Cyclo G6 Laser System and MicroPulse P3 Delivery Device, has been included in the European Glaucoma Society (EGS) Terminology and Guidelines for Glaucoma. The EGS guidelines represent recommendat
- EU Authorizes First COVID-19 Vaccine With Pfizer, BioNTech’s Comirnatyhttps://modernod.com/news/eu-authorizes-first-covid-19-vaccine-with-pfizer-biontechs-comirnaty/2478691/The European Commission on Monday granted a conditional marketing authorization to Pfizer and BioNTech’s coronavirus vaccine BNT162b2, which will go by the name Comirnaty, with the decision coming mere hours after the Committee for Medicinal Products for Human Use (CHMP) gave its backing fo
- Sifi Launches Well Fusion Presbyopia Correcting Systemhttps://modernod.com/news/sifi-launches-well-fusion-presbyopia-correcting-system/2478688/SIFI announces the launch of the Well Fusion system and the Mini Well Proxa IOL, offering a novel solution that provides cataract patients the option to treat presbyopia with spectacle-free uninterrupted high-quality vision at all distances and in all lighting conditions. SIFI has develope
- EyeGate Pharma Announces Acquisition of Panoptes Pharmahttps://modernod.com/news/eyegate-pharma-announces-acquisition-of-panoptes-pharma/2478685/EyeGate Pharmaceuticals announced the acquisition of Panoptes Pharma, a privately-held clinical stage biotech company focused on developing a novel proprietary small molecule for the treatment of severe eye diseases with a high unmet medical need. EyeGate Pharmaceuticals will pay up to $4
- Genentech’s Faricimab Meets Primary Endpoint and Shows Strong Durability Across Two Global Phase 3 Studies for DMEhttps://modernod.com/news/genentechs-faricimab-meets-primary-endpoint-and-shows-strong-durability-across-two-global-phase-3-studies-for-dme/2478687/Genentech announced positive topline results from two identically designed global phase 3 studies, YOSEMITE and RHINE, evaluating its investigational bispecific antibody, faricimab, in people living with diabetic macular edema (DME). Both studies met their primary endpoint and showed that
- CureVac and the University Medical Center Mainz Start Phase 3 Clinical Trial for COVID-19 Vaccine Candidatehttps://modernod.com/news/curevac-and-the-university-medical-center-mainz-start-phase-3-clinical-trial-for-covid-19-vaccine-candidate-cvncov-in-healthcare-workers/2478683/CureVac NV announced that the first participant in a clinical phase 3 study with its COVID-19 vaccine, CVnCoV, in healthcare workers at the University Medical Center Mainz will be vaccinated on December 22, 2020. The study aims to evaluate the safety and immunogenicity of CVnCoV administered as a